Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

European markets are expected to open slightly higher on Friday as investors look ahead to highly anticipated fiscal stimulus ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

The letter indicates that Novo Nordisk already has 55% of the market for diabetes and obesity through its blockbuster Ozempic ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...